financetom
THR
financetom
/
Industrials
/
THR
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Thermon Group Holdings, Inc.THR
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Thermon Group Holdings, Inc. provides engineered industrial process heating solutions for process industries in the United States and Latin America, Canada, Europe, the Middle East, Africa, and the Asia-Pacific.

It provides heat tracing products, such as electric heat tracing cables, steam heating solutions, controls, monitoring and software, instrumentation, project services, industrial heating and filtration solutions, temporary electrical power distribution and lighting, and other products and services.

The company also offers controls, monitoring, and software systems for the control and management of a heat trace system; environmental heating solutions under the Ruffneck, Norsemen, and Catadyne brands; process heating solutions under the Caloritech brand name; filtration solutions under the 3L Filters brand; and rail and transit solutions under the Hellfire, Velocity, ArcticSense, and other brand names.

In addition, it provides transportation heating products, including track and switch heaters, accessories, control panels, rail heaters, gas blower accessories, and air curtains; track and switch heater, gas blower accessories; transit heaters; and velocity heat.

Further, the company offers temporary power solutions; heating systems, such as engineered electric heat, explosion proof gas catalytic heaters, heaters for harshest environments, methane abatement, and engineered filtration system; electrically, steam, and fluid heated tubing bundles; and pre-insulated tubing and system accessories tubing bundles.

The company serves chemical and petrochemical, oil and gas, power generation, rail and transit, commercial, energy transition/decarbonization, mining and mineral processing, maritime/shipbuilding, semiconductors, pharmaceutical and biotechnology, food and beverage, data centers, and renewables industries through a network of sales and service professionals, and distributors.

Thermon Group Holdings, Inc. was founded in 1954 and is based in Austin, Texas.

Latest News >
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Liwei Sun, Director, President, on June 30, 2026, sold 353,624 shares in Nip Group ( NIPG ) for $442,030. Following the Form 4 filing with the SEC, Sun has control over a total of 18,095,424 Class B1 ordinary shares of the company, with 18,095,424 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1966233/000149315226031618/xslF345X05/ownership.xml ...
Argentina power firm Genneia files for US IPO
Argentina power firm Genneia files for US IPO
Jul 2, 2026
July 2 (Reuters) - Argentine power producer Genneia filed for an initial public offering in the U.S. on Thursday. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Joyjeet Das) ...
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Jul 2, 2026
06:09 AM EDT, 07/02/2026 (MT Newswires) -- Toyota Motor ( TM ) will partially cover losses worth tens of billions of yen for suppliers affected by its decision to cancel the development of an electric vehicle, Nikkei Asia reported Wednesday. The cancellation of Lexus' LF-ZC sedan has hurt the company's supply chain, with some suppliers likely facing losses of up...
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Hutchmed ( HCM ) said Thursday China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The company said the approval is based on a phase 2 study in which Orpathys achieved its primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved